Pharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
|
|
- Vivien Nichols
- 6 years ago
- Views:
Transcription
1 Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN
2 Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects Genetic factors: drug metabolizing enzymes! J Amer Med Assn, 286: , 2001 FDA CDER: Valid Genomic Biomarkers for Approved Drug Labels
3 Why do we need improved therapies? Poor efficacy Response Rates (%) 80% % % % % 0 Depression Schizophrennia Oncology Alzheimer's Incontinence HCV Osteoporosis Migraine (prophylaxis) Rheumatoid Arthritis Migraine (acute) Diabetes Asthma Cardiac arrythmias Schizophrenia Depression (SSRI) Analgesics (Cox2) From Brian Spear, Abbott
4 Drug Link in Therapeutic Area Biomarker Label Sections with Pharmacogenomic Information Abacavir Antivirals HLA-B*5701 Boxed Warning, Contraindications Warnings and Precautions Patient Counseling Carbamazepine Neurology HLA-B*1502 Boxed Warning Cetuximab Oncology EGFR KRAS Indications and Usage Warnings and Precautions Indications and Usage Clopidogrel Cardiovascular CYP2C19 Boxed Warning Dasatinib Oncology Ph Chromosome Indications and Usage Doxepin Psychiatry CYP2D6 Precautions Imatinib Oncology C-KIT, PH Chrom., PDGFR, FIP1L1- PDGFRa Indications and Usage Maraviroc Antivirals CCR5 Warnings and Precautions Tamoxifen Oncology ER Indications and Usage Trastuzumab Oncology Her-NEU Indications and Usage FDA CDER: Valid Genomic Biomarkers for Approved Drug Labels
5 FDA CDER: Valid Genomic Biomarkers for Approved Drug Labels 2010 CYP2D6 EM, PM fluoxetine, atomoxetine, venlafaxine, risperidone, olanzepine, clozepine, aripiprazol, codeine CYP2C19 EM, PM diazepam HLA-B*1502 carbamazepine, phenytoin Urea Cycle Disorder valproic acid (UCD) Deficiency* *hyperammonaemic encephalopathy, ornithine transcarbamylase (OTC) deficiency, carnitine deficiency, cerebral mitochondrial dysfunction
6 GWAS of carbamazepine-induced cutaneous ADRs (53 Japanese patients and 882 controls) Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Ozeki T et al. Hum Mol Genet. 20: (2011).
7 DRUG METABOLISM GENETICS Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics William E. Evans, Mary V. Relling Science 286:487 (1999)
8 Antidepressants and Antipsychotics Mostly lipophilic drugs that require P450 metabolism Cytochrome P450 poor metabolizers Ethnic differences CYP2D6 : 5-10% PM Caucasian, 1-3% Orientals CYP2C19: ~20% PM Orientals, 3-5% Caucasians Drug Substrates CYP2D6 : chlorpromazine, haloperidol, risperidol CYP2D6+CYP2C19: fluoxetine, nortriptyline (consider drug-drug interactions plus genotype Tanaka and Hisawa, J.Clin.Phamacol.Ther. 24: 7-16 (1999)
9 Why are PGx tests not used in Psychiatry? Which tests are clinically useful? Who is already using them? What are the costs?
10 CYP2D6 GENOTYPE-PHENOTYPE RELATIONSHIP Doxepine Genotype or or or or Phenotype ULTRARAPID METABOLIZERS EXTENSIVE METABOLIZERS INTERMEDIATE METABOLIZERS POOR METABOLIZERS Frequency (Caucasians) 5 10 % % % 5 10 % dose requirement number of patients MR= higher usual dose lower MR Meyer U.A., Nat Rev Genet 2004
11 Variability in PK - CYP2D6 and doxepin Kirchheiner et al Pharmacogenetics & Genomics 15: , Doxepin [nmol/l] PM n=9 IM n=8 EM n=14 UM n=6 P < 0.001, ANOVA hours Pharmacogenetics 2002; 12:
12 CYP2D6-based dose adjustments for antidepressants and antipsychotics % dose adjustment of a standard dose Imipramine Doxepin Maprotiline Trimipramine Desipramine Nortriptyline Clomipramine Paroxetine Venlafaxine Amitriptyline Mianserin Perphenazine Zuclopenthixol Thioridazine Aripiprazole Flupentixol Haloperidol Perazine Risperidone Ultrarapid Extensive Intermediate Poor metabolizer Mol Psychiatry 2004; 9:
13 Bottleneck: finding functional genetic variants Regulatory polymorphisms prevalent Driving evolution?? Disease models, drug response??
14 Regulatory polymorphisms studied by XGEN at OSUMC Gene Function Variant location mechanism ABDB1/MDR1 transporter synonymous mrna turnover NAT1 metabolism 3 UTR polyadenylation, translation CYP2C9 metabolism ~ -1kb promoter transcription CYP3A4 metabolism intron6 RNA elongation? CYP2D6 metabolism Exon, enhancer Splicing, expression DAT dopamine transporter intron8, 3 UTR mrna processing, translation DRD2 dopamine receptor intron5,6 ~ -1kb enhancer splicing transcription OPRM1 opioid receptor nonsynonymous RNA processing, translation CHNRA5 nicotine ~ -15kb enhancer transcription HTR2A serotonin receptor ~ -1kb promoter transcription MAOA serotonin metabolism 3 -UTR?? TPH2 Serotonin synthesis Exon8 splicing VKORC1 cardiovascular ~ -1kb promoter transcription ACE hypertension ~ -3K enhancer transcription CETP cardiovascular intron8/exon9 ~ -5kb enhancer splicing transcription
15 CYP3A4 expression in human livers Gen.Eng.News 21:29 (2001) Epidauros Biotechnologie. Bernried, Germany
16 CYP3A4 *22 allele rs Intron 6 SNP (3-8% allele frequency) affects expression 2-5 fold Decreases statin dose requirements Wang et al. TPJ 2011 Wang et al., Pharmacogenomics J. 11: (2011)
17 Dopamine and Serotonin Signaling Drug Targets: DRD2 and 5HT2A Antidepressants Atypical antipsychotics TPH2 MAOA Cocaine: DRD2 + DAT VMAT2 VMAT2 5HTR2A D2S and DAT COMT
18 Alternative splicing of the D2 dopamine receptor rs rs DRD2 gene locus E8 E6 encodes 29 AA in 3 rd cytoplasmic loop 65.5 kb E1 short (D2S): presynaptic (inhibitory); long (D2L): postsynaptic (facilitative) Intronic SNPs reduce D2S expression; multiple clinical phenotypes Zang et al. PNAS 2008
19 fmri study in normal adults during memory task Activation of striatal pathways by intronic DRD2 SNP Collaboration Alessandro Bertolino, University of Bari, Italy (PNAS 2007; Brain 2008; J. Neurosci. 2009)) SNP i6
20 Dopamine Transporter Julie Pinsonneault (npp 2011) SLC6A3 gene structure Exon Kb 5/6 repeat rs6350 Exon 2 rs rs6347 Exon 14 rs37022 rs & rs rs27072 Exon 15 rs rs VNTR Possibly 3 functional variants Impact on mrna expression in SN Association with bipolar disorder No significant effect on cocaine abuse/death
21 Dopamine signaling and lethal cocaine abuse DRD2-DAT: Gene-gene-environment interaction in cocaine abuse DAT-DRD2 SNP combination: risk OR 7-8 Sullivan et al. EPISTASIS + Drug effect
22 Next Generation Sequencing Core lab director Audrey Papp X X X X X X X X X X X X G A G A A A G A A G A G A A Whole Genome Whole transcriptome Noncoding RNAs RNA trafficking (CLIP) Allelic RNA expression Splicing Polyadenylation sites Transcription sites Antisense RNAs
23 HTR2A 5 UTR Expression promoter SNP alters TIS and translation efficiency rs6313: CT ~ 23 rs : CT ~ 27 R. Smith submitted
24 Pharmacogenomics implementation at OSUMC NIH Pharmacogenomics Research Network (TPP project, Peter Embi) Establish biomarker assays (CLIA) Store data safely prospective Transfer data to emrs Present flags upon drug prescription Provide background data link Example: clopidogrel and CYP2C19 Next generation sequencing
25 Gene-Environment Interactions: from wellness to disease - a hypothesis Frequent variants affect disease risk, symptoms, and drug response contingent upon environmental factors Environment Life style, behavior frequent variants affect normal traits Genes Epigenetics rare variants are deleterious wellness off-well illness disease
26
Table 1 Functional polymorphisms identified by XGEN group, Center for Pharmacogenomics in OSU College of Medicine.
Table 1 Functional polymorphisms identified by XGEN group, Center for Pharmacogenomics in OSU College of Medicine. Gene Functional polymorphisms or haplotypes identified Functions of polymorphisms or haplotypes
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationPharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationPsychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing
Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing CMS NEWEST GUIDELINES CMS will push nursing homes to reduce their use
More informationReview of Pharmacogenetic Testing Today
Review of Pharmacogenetic Testing Today Gwen McMillin, PhD ARUP Laboratories University of Utah Salt Lake City, Utah A customer says to the pharmacist: "Why does my medication have 40 side effects?" The
More informationPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
(2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
More informationMujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has
More informationPharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)
Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient
More informationAre health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies
Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies David Gurwitz Sackler Faculty of Medicine, Tel-Aviv University, Israel OECD,
More informationETHNICITY AND PSYCHOTROPIC RESPONSE
Ethnic Differences in Drug Metabolism ETHNICITY AND PSYCHOTROPIC RESPONSE Bridging Cultures: Improving Evaluation & Treatment of Cognitive 8 March 28 Keh-Ming Lin, M.D., M.P.H. Professor Emeritus of Psychiatry,
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationPharmacogenetics: LabQuality Days Helsinki, February 8, Do you have your DNA passport? Prof Dr Ron van Schaik
LabQuality Days Helsinki, February 8, 2018 Pharmacogenetics: Do you have your DNA passport? Prof Dr Ron van Schaik International Expert Center Pharmacogenetics Dept Clinical Chemistry - Erasmus MC Rotterdam,
More informationCYP2D6 Genotype to Phenotype Standardization Project
CYP2D6 Genotype to Phenotype Standardization Project Project Objectives Determine a strategy for defining CYP2D6 phenotype based on genotype using a modified Delphi method. Standardize phenotype definitions
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationRole of Pharmacogenomic Biomarkers In Predicting and Improving Drug Response
Role of Pharmacogenomic Biomarkers In Predicting and Improving Drug Response Part 1: The Clinical Significance of Pharmacogenetic Variants C. Lee Ventola, MS This is the first in a series of two articles
More informationGenomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
More informationI have NO actual or potential conflicts of interest in relation to this educational presentation.
Genotyping The Patient Requiring Mental Health Medications: When Does It Make Sense? Charles F. Caley, PharmD, BCPP Clinical Professor UConn School of Pharmacy Storrs, CT I have NO actual or potential
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time?
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationGenetic Testing Patient Guide
Genetic Testing Patient Guide Over the last decade, pharmacogenetics has become increasingly significant to clinical practice. Psychiatric patients, in particular, may benefit from pharmacogenetic testing
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationNew Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center
New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center Background Genetic testing Treatment options: Pharmacogenetics
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationArticle. Reference. Applications of CYP450 Testing in the Clinical Setting. SAMER, Caroline Flora, et al.
Article Applications of CYP450 Testing in the Clinical Setting SAMER, Caroline Flora, et al. Abstract Interindividual variability in drug response is a major clinical problem. Polymedication and genetic
More informationTailoring Drug Therapy Based on Genotype. Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice
Tailoring Drug Therapy Based on Genotype Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice University of Illinois at Chicago 833 S. Wood St., Rm 164 Chicago, IL 60612 Tel:
More informationPharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;
More informationRight drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing
Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing 2 Table of Contents Part One: Pharmacogenetics 101...Slides 4-16 Time Requirement: 20 minutes Part Two:
More informationHow to use pharmacogenetics to select patients for pharmaceutical care
How to use pharmacogenetics to select patients for pharmaceutical care Prof. Henk-Jan Guchelaar Dept. of Clinical Pharmacy & Toxicology Leiden University Medical Center University of Leiden PCNE Working
More informationGenomics & Personalized Medicine: Pharmacogenomics
Genomics & Personalized Medicine: Pharmacogenomics Russ B. Altman, MD, PhD Departments of Bioengineering & Genetics PharmGKB, http://www.pharmgkb.org/ Stanford University Outline of comments today Introduction
More informationPersonalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP
Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection Lindsay S. Elliott, Pharm.D., CGP Disclosure I, Lindsay Elliott, am a pharmacy consultant for Genelex Corporation in conducting
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationImipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationSupplement to: Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6
Supplement to: Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update J. Kevin Hicks 1, Katrin Sangkuhl 2, Jesse J. Swen
More informationThe Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders
Curr Behav Neurosci Rep (2015) 2:154 164 DOI 10.1007/s40473-015-0048-z MOOD AND ANXIETY DISORDERS (D IOSIFESCU, SECTION EDITOR) The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders
More informationTable of Contents. Preface Abstract Acknowledgements... 9
Table of Contents Preface... 5 Abstract... 7 Acknowledgements... 9 1. Introduction... 17 1.1 Bipolar Affective Disorder... 17 1.1.1 History and Symptomatology of Bipolar Disorder... 17 1.1.2 Pharmacotherapy...
More informationPharmacogenomics and Pharmacokinetics ^
Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning
More informationYour Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane,
1 Jane Doe DOB: 1985-01-05 Sample ID: CL-4194-DM Hello Jane, Thank you for ordering your Kailos test for antidepressants. Kailos Genetics is committed to making gene-based healthcare available to YOU.
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationPharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects Dr. Francisco Abad Santos 16 June 2017 Atypical antipsychotics or second generation antipsychotics
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationPsychiatric genomics 2018: what the clinician needs to know
Li_benefit VPA_benefit cbz_benefit Lam_benefit Combo_ms_benefit Olz_benefit Cloz_benefit Ris_benefit Quet_benefit Ari_benefit Zip_benefit Asen_benefit Luras_benefit Pali_benefit Fluphen_benefit Haldol_benefit
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationImplémentation clinique de la pharmacogénétique
Implémentation clinique de la pharmacogénétique Vincent HAUFROID Cliniques Universitaires St Luc Université catholique de Louvain Louvain centre for Toxicology and Applied Pharmacology (LTAP) Pharmacogenetics:
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytochrome p450 Genotyping Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See Also: Cytochrome p450 Genotyping Genetic Testing for Helicobacter
More informationGenomics in patients with Japanese Ancestry
Genomics in patients with Japanese Ancestry Yoshiaki Uyama, Ph.D. (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor, Graduate School of Medicine, Nagoya University
More informationCytochrome p450 Genotyping. Description. Section: Medicine Effective Date: July 15, 2015
2.04.38 Subject: Cytochrome p450 Genotyping Page: 1 of 30 Last Review Status/Date: June 2015 Cytochrome p450 Genotyping Description The cytochrome p450 (CYP450) family is involved in the metabolism of
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDeriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions!
Deriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions! Casey L. Overby 1,2, Beth Devine 1, Peter Tarczy-Hornoch 1, Ira Kalet
More informationCytochrome p450 Genotyping
Cytochrome p450 Genotyping Policy Number: Original Effective Date: MM.02.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/18/2015 Section: Medicine Place(s) of
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationPharmacogenomic testing to guide treatment using antipsychotic medications
Pharmacogenomic testing to guide treatment using antipsychotic medications Clin. Invest. (2011) 1(11), 1513 1521 This review evaluates the utilization of pharmacogenomic testing to guide treatment with
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationPharmacogenomics and Cultural Issues! Y. W. Francis Lam, Pharm.D., FCCP!
Pharmacogenomics and Cultural Issues in Psychopharmacology Y. W. Francis Lam, Pharm.D., FCCP 1 Pharmacogenomics and Cultural Issues in Psychopharmacology Y. W. Francis Lam, Pharm.D., FCCP Professor of
More informationAmerican Psychiatric Nurses Association
Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed
More informationUse of Genetics to Inform Drug Development of a Novel Treatment for Schizophrenia
Use of Genetics to Inform Drug Development of a Novel Treatment for Schizophrenia March 21, 2012 Institute of Medicine: New Paradigms in Drug Discovery Workshop Laura K. Nisenbaum, PhD Translational Medicine,
More informationPrecision Medicine Under the Big Sky
Precision Medicine Under the Big Sky Erica L. Woodahl, Ph.D. Associate Professor Department of Biomedical and Pharmaceutical Sciences University of Montana Disclosure Statement Presenter has no financial
More informationPrecision Medicine in Mental Health Care
Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans
More informationBig Data Course Week 7 Test2Learn TM 5/7/16
The site is http://api.test2learn.com Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015 Adam Suhy PhD Candidate Regulation of Cholesteryl Ester Transfer Protein and Expression of Transporters in the Blood Brain Barrier
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationWhite Paper. The Science Behind the Genecept Assay. January, 2016
White Paper The Science Behind the Genecept Assay January, 2016 Genomind, Inc. 2200 Renaissance Blvd Suite 100 King of Prussia, PA 19406 877.895.8658 www.genomind.com GEN WP003 v3 01182016 INTRODUCTION
More informationBEHAVIORAL HEALTH GENOTYPING REPORT
Health, Sally; DOB: 09/05/1988 PAGE 1 OF 5 BEHAVIORAL HEALTH GENOTYPING REPORT Patient Name: Health, Sally Date Sample Collected: 06/27/14 DOB: 09/05/1988 Date Sample Received: 07/04/14 Lab ID Number:
More informationLack of Association between Endoplasmic Reticulum Stress Response Genes and Suicidal Victims
Kobe J. Med. Sci., Vol. 53, No. 4, pp. 151-155, 2007 Lack of Association between Endoplasmic Reticulum Stress Response Genes and Suicidal Victims KAORU SAKURAI 1, NAOKI NISHIGUCHI 2, OSAMU SHIRAKAWA 2,
More informationPharmacogenomics and Customized Therapies in Psychiatry
Pharmacogenomics and Customized Therapies in Psychiatry Toshiyuki Someya,, MD, PhD Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences The efficacy and side effects
More informationOutline. Disclosures. Review of Metabolism. Central Dogma of Genetics. Introduction
Outline Psychiatric Pharmacogenomics: Applications in Nursing Personalized Health Care Phases of metabolism Function of specific genes Case Study # 1 live patient report of her experience Case Study #
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014 Elizabeth Stofko Barrie PhD Candidate Genetic Factors Regulating Expression of Dopaminergic Genes July 15 th, 2014 159 DHLRI 1:00
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationPsychiatric genomics 2016: what the clinician needs to know
Psychiatric genomics 2016: what the clinician needs to know Roy Perlis, MD MSc Center for Experimental Drugs and Diagnostics MGH Department of Psychiatry MGH Center for Human Genetic Research rperlis@partners.org
More informationCytochrome p450 Genotyping
Cytochrome p450 Genotyping Policy Number: Original Effective Date: MM.02.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2016 Section: Medicine Place(s) of
More informationJ. David Kinzie, M.D., FAC Psych Professor of Psychiatry
J. David Kinzie, M.D., FAC Psych Professor of Psychiatry I. The Evidence Against Evidence- Based Practice II. The Personal Side of Personal Medicine III. Why Epistemology is Important Example is 42-year-old
More informationPain Medication DNA Insight TM
Pain Medication DNA Insight TM TESTING SUMMARY JULY 2014 AUTHORS Alok Tomar, PhD Adrian Vilalta, PhD Pain Medication DNA Insight TM Precision Medicine and Pharmacogenetics of Pain Medications 1. Introduction
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Mental Health Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_mental_health_conditions 1/2014 6/2017 6/2018
More informationTherapeutic Drugs Monitoring TDM 2018 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More informationGenetics and pharmacogenetics of mood disorders
Psychiatr. Pol. 2017; 51(2): 197 203 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: https://doi.org/10.12740/pp/68914 Genetics and pharmacogenetics of mood disorders Alessandro
More informationCYP2D6: Genotypes, Phenotypes, and Genetic Testing
CYP2D6: Genotypes, Phenotypes, and Genetic Testing In 1975, several laboratory scientists at St. Mary s Hospital Medical School in London each ingested a 40 mg dose of debrisoquine, an antihypertensive
More information